# Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

> **NCT05227820** · PHASE2 · COMPLETED · sponsor: **Neurological Associates of West Los Angeles** · enrollment: 23 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** NE3107

## Key facts

- **NCT ID:** NCT05227820
- **Lead sponsor:** Neurological Associates of West Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-08-20
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05227820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05227820, "Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05227820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*